微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 15.71% | -12.89% | 13.31% | 143/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 13.87% | -14.69% | -9.79% | 144/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 15.37% | 4.47% | -10.76% | 144/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 17.23% | 12.16% | -4.51% | 140/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 18.04% | 28.75% | 10.97% | 136/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 16.26% | 8.16% | 10.48% | 141/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 14.72% | 40.51% | -4.19% | 139/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 15.36% | 27.56% | 9.61% | 144/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 14.01% | 5.97% | -6.78% | 142/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 15.03% | 25.57% | 43.52% | 142/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 10.47% | -11.45% | -13.02% | 141/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 12.04% | 53% | -8.94% | 144/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 13.22% | 84.11% | 10.46% | 141/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 11.97% | 88.44% | 1.21% | 141/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 11.83% | 42.56% | 50.3% | 138/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 7.87% | -66.13% | 9.57% | 147/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 7.18% | -65.86% | 13.06% | 138/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 6.35% | -72.04% | -23.43% | 142/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 8.3% | -73.82% | -64.29% | 132/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 23.23% | -38.3% | 10.44% | 137/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 21.04% | -46.94% | -7.39% | 125/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 22.72% | -44.75% | -28.31% | 132/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.69% | -5.34% | -15.86% | 101/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 37.66% | 343.62% | -5.01% | 110/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 39.65% | 1954.4% | -3.57% | 89/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 41.12% | 1524.58% | 22.82% | 92/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 33.48% | 779.22% | 779.22% | 92/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | 3.81% | 597.07% | 124.63% | 104/159 | 50.75% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | -15.46% | -3.5% | -623.01% | 130/159 | -210.26% | 微芯生物 | 96.09% | 行业排名> |
| 2017-09-30 | -2.14% | 88.42% | 25.92% | 96/159 | 48.76% | 微芯生物 | 96.11% | 行业排名> |
| 2017-06-30 | -2.89% | 83.41% | -628.41% | 102/159 | 47.61% | 微芯生物 | 95.5% | 行业排名> |
| 2017-03-31 | 0.55% | 106.59% | 103.66% | 88/159 | 46.62% | 微芯生物 | 96.27% | 行业排名> |
| 2016-12-31 | -14.94% | -2790.61% | 19.11% | 111/159 | 48.17% | 贝达药业 | 95.47% | 行业排名> |
| 2016-09-30 | -18.46% | -1379.31% | -6.11% | 81/159 | 45.83% | 贝达药业 | 95.51% | 行业排名> |
| 2016-06-30 | -17.4% | -2030.44% | -109.8% | 90/159 | 45.93% | 贝达药业 | 95.54% | 行业排名> |
| 2016-03-31 | -8.29% | -249.64% | -1505.17% | 79/159 | 43.86% | 贝达药业 | 95.74% | 行业排名> |